HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 3, 2007, Pages 1015-1020

  Goffinet, Christine ^a   Allespach, Ina ^a   Keppler, Oliver T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Animal model; Drugs; Efficacy trial

Indexed keywords

ATEVIRDINE; CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; ENFUVIRTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NONHUMAN; OUTBRED STRAIN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION; TRANSGENIC RAT; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-HIV AGENTS; ANTIGENS, CD4; CELLS, CULTURED; DISEASE SUSCEPTIBILITY; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; RATS; RECEPTORS, CCR5; REVERSE TRANSCRIPTION; T-LYMPHOCYTES; TIME FACTORS; VIRION; VIRUS INTERNALIZATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 33846505602     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0607414104     Document Type: Article

References (34)

1. Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, et al. (1998) J Acquir Immune Defic Syndr Hum Retrovirol 19:135-144.
2. Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, Bell KM, Lorentsen KJ, Hendrix CW, Petty BG, et al. (1991) Antimicrob Agents Chemother 35:2544-2550.
3. van Maanen M, Sutton RE (2003) Curr HIV Res 1:121-130.
4. Borkow G (2005) IUBMB Life 57:819-823.
5. Rabin L, Hincenbeigs M, Moreno MB, Warren S, Linquist V, Datema R, Charpiot B, Seifert J, Kaneshima H, McCune JM (1996) Antimicrob Agents Chemother 40:755-762.
6. Mosier DE (2000) Virology 271:215-219.
7. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, et al. (2005) Nature 438:99-102.
8. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, et al. (2004) Science 305:528-532.
9. Hu SL (2005) Curr Drug Targets Infect Disord 5:193-201.
10. North TW, Van Rompay KK, Higgins J, Matthews TB, Wadford DA, Pedersen NC, Schinazi RF (2005) J Virol 79:7349-7354.
11. Giuffre AC, Higgins J, Buckheit RW, Jr, North TW (2003) Antimicrob Agents Chemother 47:1756-1759.
12. Keppler OT, Yonemoto W, Welte FJ, Patton KS, Iacovides D, Atchison RE, Ngo T, Hirschberg DL, Speck RF, Goldsmith MA (2001) J Virol 75:8063-8073.
13. Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, et al. (2002) J Exp Med 195:719-736.
14. Jones G, Zhu Y, Silva C, Tsutsui S, Pardo CA, Keppler OT, McArthur JC, Power C (2005) Virology 334:178-193.
15. Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, Gill MJ, Power C (2006) Ann Neurol 59:816-824.
16. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W (2004) Antivir Ther 9:57-65.
17. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, et al. (1998) Nat Med 4:1302-1307.
18. Venzke S, Michel N, Allespach I, Fackler OT, Keppler OT (2006) J Virol 80:11141-11152.
19. Cavrois M, De Noronha C, Greene WC (2002) Nat Biotechnol 20:1151-1154.
20. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, et al. (2000) Nat Med 6:76-81.
21. Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Hawkins E, Sista P, Cunningham CK (2004) Pediatr Infect Dis J 23:713-718.
22. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, et al. (2000) Antimicrob Agents Chemother 44:2475-2484.
23. Abbott A (2004) Nature 428:464-466.
24. Venzke S, Keppler OT (2006) Expert Rev Clin Immunol 2:613-626.
25. Jong A, Huang SH (2005) Curr Drug Targets Infect Disord 5:65-72.
26. Ghosn J, Chaix ML, Peytavin G, Rey E, Bresson JL, Goujard C, Katlama C, Viard JP, Treluyer JM, Rouzioux C (2004) AIDS 18:1958-1961.
27. Garbuglia AR, Zaccarelli M, Calcaterra S, Cappiello G, Marini R, Benedetto A (2001) J Chemother 13:188-194.
28. Goffinet C, Keppler OT (2006) FASEB J 20:500-502.
29. Keppler OT, Allespach I, Schuller L, Fenard D, Greene WC, Fackler OT (2005) J Virol 79:1655-1665.
30. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH (1991) J Virol 65:3973-3985.
31. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, et al. (1997) Nature 385:645-649.
32. Reuter S, Kaumanns P, Buschhorn SB, Dittmar MT (2005) Virology 332:347-358.
33. Van Maele B, De Rijck J, DeClercq E, Debyser Z (2003) J Virol 77:4685-4694.
34. Brussel A, Sonigo P (2003) J Virol 77:10119-10124.